Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by NewAmsterdam Pharma N.V

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces 2024 Strategic Priorities
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference
From NewAmsterdam Pharma N.V
Via GlobeNewswire
Tickers NAMS NAMSW
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.